Moderna (MRNA) debt: $590M
Moderna had $590M of long-term debt on Dec 31, 2025, including the part due within a year.
From Moderna's filings with the SEC · Read the filing · MRNA stock page
Moderna debt by year
#1,062 of 2,129 US companies by debt · See the full ranking
| Year ended | Debt | Change |
|---|---|---|
| Dec 31, 2025 | $590M | – |
Debt of similar companies
Companies in the same industry as Moderna, by SEC industry code, with the closest debt. Each name opens the same page for that company.
| Company | Debt, latest year | Year ended |
|---|---|---|
| Halozyme Therapeutics | $2.1B | Dec 31, 2025 |
| Qiagen | $1.7B | Dec 31, 2025 |
| Moderna | $590M | Dec 31, 2025 |
| Repligen | $542M | Dec 31, 2025 |
| Novavax | $244M | Dec 31, 2025 |
| Adaptive Biotechnologies | $131M | Dec 31, 2025 |
| Inhibrx Biosciences | $101M | Dec 31, 2025 |
Questions and answers
What is Moderna's debt?
Moderna had $590M of long-term debt on Dec 31, 2025, including the part due within a year.
Numbers as reported in Moderna's annual and quarterly reports to the SEC (XBRL data). A year is the company's fiscal year that falls mostly in that calendar year; balances such as cash and debt are as of the date shown. Data only, not investment advice. Methodology